Dialysis Deaths From Fresenius GranuFlo Product
Levin Papantonio attorney interviewed by LAW360 about a breaking product liability scenario regarding Fresenius, the manufacturer of the dialysis agent GranuFlo. Apparently, the FDA was “leaked” an internal memo where Fresenius executives concluded that dialysis patients had a 6x higher likely hood of a death by cardiopulmonary arrest if they were using GranuFlo, as compared to other dialysis agents. Lawyers say patients are concerned about complications and side effects of the GranuFlo product, and we may see personal lawsuits and class action lawsuits involving Granuflo related deaths. Fresenius sells about $100mm/year of the Granuflo product for use by kidney dialysis patients. According to public information, the company is well financed, with a market capitalization of $20B.
BY: BRANDON BOGLE
Regular Ring of Fire Radio listeners and visitors to the show's website may have seen a recent article by the show's producer, Farron Cousins, regarding pending cases against German-based pharmaceutical firm Fresenius and its flagship product, Granuflo . In the article, Mr. Cousins reports that Fresenius is claiming plaintiffs injured by their dialysis drug have no case. Not only are allegations of “failure to warn” groundless, company attorneys say, there were no dangers in the first place!
NEWS ARTICLE – NY TIMES